Home About Us Pipeline News Investors Contacts Careers


Puma Biotechnology, Inc. Corporate Fact Sheet


NEWS

EVENTS

CONTACT


September 20, 2016 - Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

August 22, 2016 - Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
Read

August 9, 2016 - Puma Biotechnology Reports Second Quarter 2016 Financial Results
Read

July 21, 2016 - Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
Read

July 21, 2016 - Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

July 7, 2016 - Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine
Read

June 27, 2016 - Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
Read

June 5, 2016 - Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
Read


  • July 21, 2016 - Puma Biotechnology Update Call
    More

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
info@pumabiotechnology.com


Puma Biotechnology 2015 Annual Report

 Annual Report Archives